News

   

Asgard Therapeutics announces publication in Immunity demonstrating induction of cancer-fighting tertiary lymphoid structures across seven tumor types – and will present new AT-108 biomarker data at SITC 2026

Study in Immunity highlights Asgard's ability to generate…

AC Immune Third Quarter 2026 Financial and Corporate Update

Positive clinical and regulatory progress achieved across wholly-owned…

Hansa Biopharma to participate in BIO-Europe 2026

Lund, Sweden, November 4. Hansa Biopharma AB, “Hansa” (Nasdaq…

New research initiative will utilise AI to optimise Nordic energy grid capacity, improve resilience and prepare for future needs

A new Nordic research initiative will develop artificial intelligence-based…

Sofinnova Partners promotes Javier Nunez-Vicandi to Partner, strengthening its Digital Medicine strategy

Physician-investor and co-builder of Sofinnova's AI platform…

Hansa Biopharma to participate in the BioStock Life Science Summit

Lund, Sweden, October 30. Hansa Biopharma AB, “Hansa” (Nasdaq…

iOnctura to present late-breaking data on roginolisib in immunotherapy-resistant NSCLC at SITC

Data from the ongoing PULMO-01 clinical study to be presented…

Exogenus Therapeutics leads a €13 million EU-funded consortium to advance a new secretome-based therapy for osteoarthritis

ExoCordOA, a five-year project, led by Exogenus Therapeutics…

Simris Group appoints experienced ADC clinical development leader Dr. András Strassz as Chief Medical Officer

Hammenhög, Sweden, October 29, 2026: Simris Group AB (publ)…

ALLOX closes $10.5M seed financing and appoints Morten Graugaard as Chair to scale allosteric drug discovery platform and build pipeline

Financing led by Asabys, with participation from CDTI with…

Hansa Biopharma to host Q3 2026 interim results conference call

Lund, Sweden, October 28, 2026. Hansa Biopharma, “Hansa”…

Oncoinvent appoints Dr. Zuzana Jiráková Trnková as Chief Medical Officer to lead Phase 3 preparations for Radspherin®

  Dr. Jiráková Trnková brings more than 20 years of…

Octane Biotech and Currus Biologics Automate Manufacturing of CUR-001 CAR T-Cell Therapy on the Cocoon® Platform

Automated, closed-system process to support Currus’ Phase 1…

Hansa Biopharma announces positive Idefirix PAES results presented in the High-Impact Clinical Trials session at ASN Kidney Week

The 1-year graft failure-free survival at 12 months post-transplant…

New long-term and real-world data on BRIUMVI® (ublituximab) presented at the 10th Joint ACTRIMS-ECTRIMS Meeting 2026

New scientific data in relapsing forms of multiple sclerosis…

Hansa Biopharma announces Idefirix PAES late-breaking abstract selected for oral presentation in High-Impact Clinical Trials session at ASN Kidney Week

Lund, Sweden, October 20, 2026. Hansa Biopharma AB, “Hansa”…

Hansa Biopharma announces submission of IND Application to US FDA for HNSA-5487 in GBS

The IND submission marks an important milestone in advancing…

Gesynta Pharma completes enrollment in Phase 2 NOVA trial evaluating vipoglanstat in endometriosis

Enrollment completed three months ahead of schedule NOVA…

Mestag Therapeutics Appoints Philip Astley-Sparke and Victor Sandor, M.D.C.M., to its Board of Directors

— Mr. Astley-Sparke brings more than two decades of biotech…

R1 Therapeutics to present Phase 2b trial-in-progress poster for AP306 at ASN Kidney Week 2026

Poster will outline the design of R1’s ongoing global…

We’d love to hear from you.

For more information about Optimum Strategic Communications, please get in touch.

Get in touch
© Optimum Strategic Communications.